Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK127 and AK112 in Advanced Solid Tumors
NCT05951608Phase 2Active, not recruiting
- Sponsor
- Akeso, Inc.
- Start
- Oct 2023
- Primary completion
- May 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of AK127 in solid tumor, sponsored by Akeso, Inc.. Started Oct 2023; status: active, not recruiting.
02
Drugs
AK127
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05951608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05951608.